Influence of SARS-CoV-2 variants and corticosteroid use on the effectiveness of baricitinib therapy in critical COVID-19

IF 8.8 1区 医学 Q1 CRITICAL CARE MEDICINE
Seung-Hun You, Moon Seong Baek, Tae Wan Kim, Sun-Young Jung, Won-Young Kim
{"title":"Influence of SARS-CoV-2 variants and corticosteroid use on the effectiveness of baricitinib therapy in critical COVID-19","authors":"Seung-Hun You, Moon Seong Baek, Tae Wan Kim, Sun-Young Jung, Won-Young Kim","doi":"10.1186/s13054-025-05367-x","DOIUrl":null,"url":null,"abstract":"<p>Dear Editor,</p><p>We sincerely appreciate the insightful comments provided by Li et al. [1] regarding our correspondence, “Baricitinib versus tocilizumab in mechanically ventilated patients with COVID-19: a nationwide cohort study” [2], recently published in <i>Critical Care</i>. We recognize the need for further clarification on certain aspects to ensure a more precise interpretation of our study findings.</p><p>We acknowledge that the emergence of multiple SARS-CoV-2 variants over time could have influenced the therapeutic efficacy of baricitinib and tocilizumab in critically ill patients with COVID-19. Our cohort analysis accounted for temporal variations by stratifying patients based on their inclusion earlier or later in the pandemic. To provide a more granular assessment, we reanalyzed the outcomes by stratifying them according to the predominant SARS-CoV-2 strains circulating in Korea during the study period: Delta (July 2021–December 2021) and Omicron (January 2022–October 2022). The wild-type and Alpha periods were excluded from the analysis, as baricitinib and tocilizumab had not yet been authorized for use in Korea during these phases. Our findings revealed no significant differences in outcomes between patients receiving baricitinib or tocilizumab during the Delta-dominant period. However, during the Omicron-dominant period, patients treated with baricitinib exhibited significantly lower 30-day mortality rates compared to those receiving tocilizumab (53.8% vs 61.5%; odds ratio 0.73; 95% confidence interval 0.56–0.95). This finding aligns with a previous cohort study demonstrating that baricitinib was more effective in mitigating the inflammatory response triggered by the Omicron variant [3]. Among the 98 of 1630 (6.0%) patients hospitalized due to reinfection, only 14 required mechanical ventilation (MV). Consequently, it was not feasible to determine whether the clinical outcomes associated with baricitinib differed in this subgroup of patients.</p><p>As noted by Li et al., the concurrent use of corticosteroids could potentially influence the immunomodulatory effects of baricitinib and tocilizumab. The authors suggested conducting a subgroup analysis based on corticosteroid use. However, nearly all patients (98.4% of the initial cohort) received corticosteroids. Therefore, instead of a binary analysis based on corticosteroid administration, we performed subgroup analyses of 30-day mortality based on corticosteroid dosage and treatment duration. Corticosteroid use was defined as the administration of at least one dose of intravenous dexamethasone, hydrocortisone, or methylprednisolone during hospitalization. To standardize comparisons, all doses were converted to prednisolone equivalents [4]. The cut-off values for daily steroid dose and total treatment duration were determined based on the mean values observed in the study population. Among patients who received corticosteroids for fewer than 12 days or at a daily dose below 60 mg, the baricitinib group exhibited significantly lower mortality rates than the tocilizumab group (Fig. 1). However, when corticosteroid treatment extended to 12 or more days, or when the daily dose reached 60 mg or higher, no significant differences in 30-day mortality were observed between the groups. These findings suggest that the beneficial effects of baricitinib may be more pronounced in patients with critical COVID-19 receiving lower corticosteroid doses. Further studies are warranted to investigate the interplay between corticosteroids, other immunomodulatory agents, and clinical outcomes.</p><figure><figcaption><b data-test=\"figure-caption-text\">Fig. 1</b></figcaption><picture><img alt=\"figure 1\" aria-describedby=\"Fig1\" height=\"180\" loading=\"lazy\" src=\"//media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13054-025-05367-x/MediaObjects/13054_2025_5367_Fig1_HTML.png\" width=\"685\"/></picture><p>Association of baricitinib on 30-day mortality based on corticosteroid dosage and treatment duration. Odds ratios (represented by squares) and 95% CIs (depicted by horizontal lines) were calculated for the baricitinib (n = 553) and tocilizumab (n = 553) groups. <i>CI</i> confidence interval</p><span>Full size image</span><svg aria-hidden=\"true\" focusable=\"false\" height=\"16\" role=\"img\" width=\"16\"><use xlink:href=\"#icon-eds-i-chevron-right-small\" xmlns:xlink=\"http://www.w3.org/1999/xlink\"></use></svg></figure><p>Contrary to the authors’ comment, we had provided the duration of therapy with baricitinib and tocilizumab in the original paper [2]. In both the unmatched and propensity score-matched groups, the median (interquartile range) durations of baricitinib and tocilizumab use were 8 (4–13) days and 1 (1–1) day, respectively. The duration of baricitinib use aligns with previously reported values (7–8 days) [3, 5]. The daily dose of each drug was not calculated, as prescriptions may not always accurately reflect actual treatment. However, based on Korean COVID-19 treatment guidelines [6], the dosage was likely consistent at approximately 4 mg/day for baricitinib and 8 mg/kg/day for tocilizumab. We would like to clarify that baricitinib was associated with lower 30-day mortality than tocilizumab in the overall cohort of patients with COVID-19 requiring MV. This finding contrasts with previous studies that reported no significant benefit of baricitinib in mechanically ventilated patients [7, 8]. As noted by Li et al., the efficacy of baricitinib may be reduced in patients with gastrointestinal malabsorption or renal dysfunction, both of which are frequently observed in those receiving MV [8, 9]. However, the administration of baricitinib over multiple days may ensure more stable drug concentrations. Furthermore, its association with reduced 30-day mortality has been consistently observed in patients undergoing renal replacement therapy.</p><p>Among mechanically ventilated patients with COVID-19, baricitinib was associated with lower 30-day mortality than tocilizumab, particularly during the Omicron period and among those receiving lower doses of corticosteroids. We hope these clarifications address the concerns raised by the authors and further enhance the interpretation of our study findings.</p><p>All data generated or analyzed during this study are included in this published article.</p><dl><dt style=\"min-width:50px;\"><dfn>MV:</dfn></dt><dd>\n<p>Mechanical ventilation</p>\n</dd></dl><ol data-track-component=\"outbound reference\" data-track-context=\"references section\"><li data-counter=\"1.\"><p>Li R, Wang J, Li Q, Guo Q, Zhao JK, Wei JC, et al. Comments on “Baricitinib versus tocilizumab in mechanically ventilated patients with COVID-19: a nationwide cohort study.” Crit Care. 2024;28:428.</p><p>PubMed PubMed Central Google Scholar </p></li><li data-counter=\"2.\"><p>You SH, Baek MS, Kim TW, Jung SY, Kim WY. Baricitinib versus tocilizumab in mechanically ventilated patients with COVID-19: a nationwide cohort study. Crit Care. 2024;28:282.</p><p>PubMed PubMed Central Google Scholar </p></li><li data-counter=\"3.\"><p>Sunny S, Tran A, Lee J, Abdallah M, Chaudhry N, Quale J. Comparison of tocilizumab vs baricitinib in clinical outcomes among hospitalized patients with COVID-19: experience from a public hospital system in New York City. Open Forum Infect Dis. 2023;10:ofad26.</p><p>Google Scholar </p></li><li data-counter=\"4.\"><p>Meikle AW, Tyler FH. Potency and duration of action of glucocorticoids. Effects of hydrocortisone, prednisone and dexamethasone on human pituitary-adrenal function. Am J Med. 1977;63:200–27.</p><p>CAS PubMed Google Scholar </p></li><li data-counter=\"5.\"><p>Peterson JH, Paranjape NS, Grundlingh N, Priestley JL. Outcomes and adverse effects of baricitinib versus tocilizumab in the management of severe COVID-19. Crit Care Med. 2023;51:337–46.</p><p>CAS PubMed Google Scholar </p></li><li data-counter=\"6.\"><p>National Medical Center—Office for the Central Infectious Disease Hospital—National Institute of Infectious Diseases. Clinical practice guideline for coronavirus disease 2019 (COVID-19). https://www.nmc.or.kr/icd/bbs/B0000070/list.do?menuNo=1300032 (2022). Accessed 12 Apr 2024.</p></li><li data-counter=\"7.\"><p>RECOVERY Collaborative Group. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. Lancet. 2022;400:359–68.</p><p>Google Scholar </p></li><li data-counter=\"8.\"><p>Patanwala AE, Xiao X, Hills TE, Higgins AM, McArthur CJ, Alexander GC, et al. Comparative effectiveness of baricitinib versus tocilizumab in hospitalized patients with COVID-19: a retrospective cohort study of the National Covid Collaborative. Crit Care Med. 2025;53:e29-41.</p><p>CAS PubMed Google Scholar </p></li><li data-counter=\"9.\"><p>Reintam Blaser A, Poeze M, Malbrain ML, Bjorck M, Oudemans-van Straaten HM, Starkopf J, et al. Gastrointestinal symptoms during the first week of intensive care are associated with poor outcome: a prospective multicentre study. Intens Care Med. 2013;39:899–909.</p><p>Google Scholar </p></li></ol><p>Download references<svg aria-hidden=\"true\" focusable=\"false\" height=\"16\" role=\"img\" width=\"16\"><use xlink:href=\"#icon-eds-i-download-medium\" xmlns:xlink=\"http://www.w3.org/1999/xlink\"></use></svg></p><p>This study used the database of the Korea Disease Control and Prevention Agency and the National Health Insurance Service for policy and academic research (KDCA-NHIS-2023-1-488).</p><p>This research was supported by the National Research Foundation of Korea grant funded by the Korea government (Ministry of Science, ICT &amp; Future Planning) (2022R1F1A1067609). The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication.</p><h3>Authors and Affiliations</h3><ol><li><p>Department of Global Innovative Drugs, The Graduate School of Chung-Ang University, Chung-Ang University, Seoul, Republic of Korea</p><p>Seung-Hun You &amp; Sun-Young Jung</p></li><li><p>Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Republic of Korea</p><p>Moon Seong Baek, Tae Wan Kim &amp; Won-Young Kim</p></li><li><p>College of Pharmacy, Chung-Ang University, Seoul, Republic of Korea</p><p>Sun-Young Jung</p></li></ol><span>Authors</span><ol><li><span>Seung-Hun You</span>View author publications<p><span>You can also search for this author in</span><span>PubMed<span> </span>Google Scholar</span></p></li><li><span>Moon Seong Baek</span>View author publications<p><span>You can also search for this author in</span><span>PubMed<span> </span>Google Scholar</span></p></li><li><span>Tae Wan Kim</span>View author publications<p><span>You can also search for this author in</span><span>PubMed<span> </span>Google Scholar</span></p></li><li><span>Sun-Young Jung</span>View author publications<p><span>You can also search for this author in</span><span>PubMed<span> </span>Google Scholar</span></p></li><li><span>Won-Young Kim</span>View author publications<p><span>You can also search for this author in</span><span>PubMed<span> </span>Google Scholar</span></p></li></ol><h3>Contributions</h3><p>WYK participated in the conception and design of study. SYJ and SHY participated in the data acquisition and data analysis. WYK, SYJ, MSB, and TWK participated in the data interpretation. WYK and SHY participated in the draft of the manuscript. SYJ, MSB, and TWK helped to revise the manuscript for important intellectual content. All authors read and approved the final manuscript.</p><h3>Corresponding authors</h3><p>Correspondence to Sun-Young Jung or Won-Young Kim.</p><h3>Ethics approval and consent to participate</h3>\n<p>The study protocol for the utilization of de-identified patient data was exempt from review by the Institutional Review Board of Chung-Ang University (1041078-20230306-HR-055).</p>\n<h3>Consent for publication</h3>\n<p>Not applicable.</p>\n<h3>Competing interests</h3>\n<p>The authors declare no competing interests.</p><h3>Publisher's Note</h3><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p><p><b>Open Access</b> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.</p>\n<p>Reprints and permissions</p><img alt=\"Check for updates. Verify currency and authenticity via CrossMark\" height=\"81\" loading=\"lazy\" src=\"data:image/svg+xml;base64,<svg height="81" width="57" xmlns="http://www.w3.org/2000/svg"><g fill="none" fill-rule="evenodd"><path d="m17.35 35.45 21.3-14.2v-17.03h-21.3" fill="#989898"/><path d="m38.65 35.45-21.3-14.2v-17.03h21.3" fill="#747474"/><path d="m28 .5c-12.98 0-23.5 10.52-23.5 23.5s10.52 23.5 23.5 23.5 23.5-10.52 23.5-23.5c0-6.23-2.48-12.21-6.88-16.62-4.41-4.4-10.39-6.88-16.62-6.88zm0 41.25c-9.8 0-17.75-7.95-17.75-17.75s7.95-17.75 17.75-17.75 17.75 7.95 17.75 17.75c0 4.71-1.87 9.22-5.2 12.55s-7.84 5.2-12.55 5.2z" fill="#535353"/><path d="m41 36c-5.81 6.23-15.23 7.45-22.43 2.9-7.21-4.55-10.16-13.57-7.03-21.5l-4.92-3.11c-4.95 10.7-1.19 23.42 8.78 29.71 9.97 6.3 23.07 4.22 30.6-4.86z" fill="#9c9c9c"/><path d="m.2 58.45c0-.75.11-1.42.33-2.01s.52-1.09.91-1.5c.38-.41.83-.73 1.34-.94.51-.22 1.06-.32 1.65-.32.56 0 1.06.11 1.51.35.44.23.81.5 1.1.81l-.91 1.01c-.24-.24-.49-.42-.75-.56-.27-.13-.58-.2-.93-.2-.39 0-.73.08-1.05.23-.31.16-.58.37-.81.66-.23.28-.41.63-.53 1.04-.13.41-.19.88-.19 1.39 0 1.04.23 1.86.68 2.46.45.59 1.06.88 1.84.88.41 0 .77-.07 1.07-.23s.59-.39.85-.68l.91 1c-.38.43-.8.76-1.28.99-.47.22-1 .34-1.58.34-.59 0-1.13-.1-1.64-.31-.5-.2-.94-.51-1.31-.91-.38-.4-.67-.9-.88-1.48-.22-.59-.33-1.26-.33-2.02zm8.4-5.33h1.61v2.54l-.05 1.33c.29-.27.61-.51.96-.72s.76-.31 1.24-.31c.73 0 1.27.23 1.61.71.33.47.5 1.14.5 2.02v4.31h-1.61v-4.1c0-.57-.08-.97-.25-1.21-.17-.23-.45-.35-.83-.35-.3 0-.56.08-.79.22-.23.15-.49.36-.78.64v4.8h-1.61zm7.37 6.45c0-.56.09-1.06.26-1.51.18-.45.42-.83.71-1.14.29-.3.63-.54 1.01-.71.39-.17.78-.25 1.18-.25.47 0 .88.08 1.23.24.36.16.65.38.89.67s.42.63.54 1.03c.12.41.18.84.18 1.32 0 .32-.02.57-.07.76h-4.36c.07.62.29 1.1.65 1.44.36.33.82.5 1.38.5.29 0 .57-.04.83-.13s.51-.21.76-.37l.55 1.01c-.33.21-.69.39-1.09.53-.41.14-.83.21-1.26.21-.48 0-.92-.08-1.34-.25-.41-.16-.76-.4-1.07-.7-.31-.31-.55-.69-.72-1.13-.18-.44-.26-.95-.26-1.52zm4.6-.62c0-.55-.11-.98-.34-1.28-.23-.31-.58-.47-1.06-.47-.41 0-.77.15-1.07.45-.31.29-.5.73-.58 1.3zm2.5.62c0-.57.09-1.08.28-1.53.18-.44.43-.82.75-1.13s.69-.54 1.1-.71c.42-.16.85-.24 1.31-.24.45 0 .84.08 1.17.23s.61.34.85.57l-.77 1.02c-.19-.16-.38-.28-.56-.37-.19-.09-.39-.14-.61-.14-.56 0-1.01.21-1.35.63-.35.41-.52.97-.52 1.67 0 .69.17 1.24.51 1.66.34.41.78.62 1.32.62.28 0 .54-.06.78-.17.24-.12.45-.26.64-.42l.67 1.03c-.33.29-.69.51-1.08.65-.39.15-.78.23-1.18.23-.46 0-.9-.08-1.31-.24-.4-.16-.75-.39-1.05-.7s-.53-.69-.7-1.13c-.17-.45-.25-.96-.25-1.53zm6.91-6.45h1.58v6.17h.05l2.54-3.16h1.77l-2.35 2.8 2.59 4.07h-1.75l-1.77-2.98-1.08 1.23v1.75h-1.58zm13.69 1.27c-.25-.11-.5-.17-.75-.17-.58 0-.87.39-.87 1.16v.75h1.34v1.27h-1.34v5.6h-1.61v-5.6h-.92v-1.2l.92-.07v-.72c0-.35.04-.68.13-.98.08-.31.21-.57.4-.79s.42-.39.71-.51c.28-.12.63-.18 1.04-.18.24 0 .48.02.69.07.22.05.41.1.57.17zm.48 5.18c0-.57.09-1.08.27-1.53.17-.44.41-.82.72-1.13.3-.31.65-.54 1.04-.71.39-.16.8-.24 1.23-.24s.84.08 1.24.24c.4.17.74.4 1.04.71s.54.69.72 1.13c.19.45.28.96.28 1.53s-.09 1.08-.28 1.53c-.18.44-.42.82-.72 1.13s-.64.54-1.04.7-.81.24-1.24.24-.84-.08-1.23-.24-.74-.39-1.04-.7c-.31-.31-.55-.69-.72-1.13-.18-.45-.27-.96-.27-1.53zm1.65 0c0 .69.14 1.24.43 1.66.28.41.68.62 1.18.62.51 0 .9-.21 1.19-.62.29-.42.44-.97.44-1.66 0-.7-.15-1.26-.44-1.67-.29-.42-.68-.63-1.19-.63-.5 0-.9.21-1.18.63-.29.41-.43.97-.43 1.67zm6.48-3.44h1.33l.12 1.21h.05c.24-.44.54-.79.88-1.02.35-.24.7-.36 1.07-.36.32 0 .59.05.78.14l-.28 1.4-.33-.09c-.11-.01-.23-.02-.38-.02-.27 0-.56.1-.86.31s-.55.58-.77 1.1v4.2h-1.61zm-47.87 15h1.61v4.1c0 .57.08.97.25 1.2.17.24.44.35.81.35.3 0 .57-.07.8-.22.22-.15.47-.39.73-.73v-4.7h1.61v6.87h-1.32l-.12-1.01h-.04c-.3.36-.63.64-.98.86-.35.21-.76.32-1.24.32-.73 0-1.27-.24-1.61-.71-.33-.47-.5-1.14-.5-2.02zm9.46 7.43v2.16h-1.61v-9.59h1.33l.12.72h.05c.29-.24.61-.45.97-.63.35-.17.72-.26 1.1-.26.43 0 .81.08 1.15.24.33.17.61.4.84.71.24.31.41.68.53 1.11.13.42.19.91.19 1.44 0 .59-.09 1.11-.25 1.57-.16.47-.38.85-.65 1.16-.27.32-.58.56-.94.73-.35.16-.72.25-1.1.25-.3 0-.6-.07-.9-.2s-.59-.31-.87-.56zm0-2.3c.26.22.5.37.73.45.24.09.46.13.66.13.46 0 .84-.2 1.15-.6.31-.39.46-.98.46-1.77 0-.69-.12-1.22-.35-1.61-.23-.38-.61-.57-1.13-.57-.49 0-.99.26-1.52.77zm5.87-1.69c0-.56.08-1.06.25-1.51.16-.45.37-.83.65-1.14.27-.3.58-.54.93-.71s.71-.25 1.08-.25c.39 0 .73.07 1 .2.27.14.54.32.81.55l-.06-1.1v-2.49h1.61v9.88h-1.33l-.11-.74h-.06c-.25.25-.54.46-.88.64-.33.18-.69.27-1.06.27-.87 0-1.56-.32-2.07-.95s-.76-1.51-.76-2.65zm1.67-.01c0 .74.13 1.31.4 1.7.26.38.65.58 1.15.58.51 0 .99-.26 1.44-.77v-3.21c-.24-.21-.48-.36-.7-.45-.23-.08-.46-.12-.7-.12-.45 0-.82.19-1.13.59-.31.39-.46.95-.46 1.68zm6.35 1.59c0-.73.32-1.3.97-1.71.64-.4 1.67-.68 3.08-.84 0-.17-.02-.34-.07-.51-.05-.16-.12-.3-.22-.43s-.22-.22-.38-.3c-.15-.06-.34-.1-.58-.1-.34 0-.68.07-1 .2s-.63.29-.93.47l-.59-1.08c.39-.24.81-.45 1.28-.63.47-.17.99-.26 1.54-.26.86 0 1.51.25 1.93.76s.63 1.25.63 2.21v4.07h-1.32l-.12-.76h-.05c-.3.27-.63.48-.98.66s-.73.27-1.14.27c-.61 0-1.1-.19-1.48-.56-.38-.36-.57-.85-.57-1.46zm1.57-.12c0 .3.09.53.27.67.19.14.42.21.71.21.28 0 .54-.07.77-.2s.48-.31.73-.56v-1.54c-.47.06-.86.13-1.18.23-.31.09-.57.19-.76.31s-.33.25-.41.4c-.09.15-.13.31-.13.48zm6.29-3.63h-.98v-1.2l1.06-.07.2-1.88h1.34v1.88h1.75v1.27h-1.75v3.28c0 .8.32 1.2.97 1.2.12 0 .24-.01.37-.04.12-.03.24-.07.34-.11l.28 1.19c-.19.06-.4.12-.64.17-.23.05-.49.08-.76.08-.4 0-.74-.06-1.02-.18-.27-.13-.49-.3-.67-.52-.17-.21-.3-.48-.37-.78-.08-.3-.12-.64-.12-1.01zm4.36 2.17c0-.56.09-1.06.27-1.51s.41-.83.71-1.14c.29-.3.63-.54 1.01-.71.39-.17.78-.25 1.18-.25.47 0 .88.08 1.23.24.36.16.65.38.89.67s.42.63.54 1.03c.12.41.18.84.18 1.32 0 .32-.02.57-.07.76h-4.37c.08.62.29 1.1.65 1.44.36.33.82.5 1.38.5.3 0 .58-.04.84-.13.25-.09.51-.21.76-.37l.54 1.01c-.32.21-.69.39-1.09.53s-.82.21-1.26.21c-.47 0-.92-.08-1.33-.25-.41-.16-.77-.4-1.08-.7-.3-.31-.54-.69-.72-1.13-.17-.44-.26-.95-.26-1.52zm4.61-.62c0-.55-.11-.98-.34-1.28-.23-.31-.58-.47-1.06-.47-.41 0-.77.15-1.08.45-.31.29-.5.73-.57 1.3zm3.01 2.23c.31.24.61.43.92.57.3.13.63.2.98.2.38 0 .65-.08.83-.23s.27-.35.27-.6c0-.14-.05-.26-.13-.37-.08-.1-.2-.2-.34-.28-.14-.09-.29-.16-.47-.23l-.53-.22c-.23-.09-.46-.18-.69-.3-.23-.11-.44-.24-.62-.4s-.33-.35-.45-.55c-.12-.21-.18-.46-.18-.75 0-.61.23-1.1.68-1.49.44-.38 1.06-.57 1.83-.57.48 0 .91.08 1.29.25s.71.36.99.57l-.74.98c-.24-.17-.49-.32-.73-.42-.25-.11-.51-.16-.78-.16-.35 0-.6.07-.76.21-.17.15-.25.33-.25.54 0 .14.04.26.12.36s.18.18.31.26c.14.07.29.14.46.21l.54.19c.23.09.47.18.7.29s.44.24.64.4c.19.16.34.35.46.58.11.23.17.5.17.82 0 .3-.06.58-.17.83-.12.26-.29.48-.51.68-.23.19-.51.34-.84.45-.34.11-.72.17-1.15.17-.48 0-.95-.09-1.41-.27-.46-.19-.86-.41-1.2-.68z" fill="#535353"/></g></svg>\" width=\"57\"/><h3>Cite this article</h3><p>You, SH., Baek, M.S., Kim, T.W. <i>et al.</i> Influence of SARS-CoV-2 variants and corticosteroid use on the effectiveness of baricitinib therapy in critical COVID-19. <i>Crit Care</i> <b>29</b>, 131 (2025). https://doi.org/10.1186/s13054-025-05367-x</p><p>Download citation<svg aria-hidden=\"true\" focusable=\"false\" height=\"16\" role=\"img\" width=\"16\"><use xlink:href=\"#icon-eds-i-download-medium\" xmlns:xlink=\"http://www.w3.org/1999/xlink\"></use></svg></p><ul data-test=\"publication-history\"><li><p>Received<span>: </span><span><time datetime=\"2025-03-07\">07 March 2025</time></span></p></li><li><p>Accepted<span>: </span><span><time datetime=\"2025-03-11\">11 March 2025</time></span></p></li><li><p>Published<span>: </span><span><time datetime=\"2025-03-22\">22 March 2025</time></span></p></li><li><p>DOI</abbr><span>: </span><span>https://doi.org/10.1186/s13054-025-05367-x</span></p></li></ul><h3>Share this article</h3><p>Anyone you share the following link with will be able to read this content:</p><button data-track=\"click\" data-track-action=\"get shareable link\" data-track-external=\"\" data-track-label=\"button\" type=\"button\">Get shareable link</button><p>Sorry, a shareable link is not currently available for this article.</p><p data-track=\"click\" data-track-action=\"select share url\" data-track-label=\"button\"></p><button data-track=\"click\" data-track-action=\"copy share url\" data-track-external=\"\" data-track-label=\"button\" type=\"button\">Copy to clipboard</button><p> Provided by the Springer Nature SharedIt content-sharing initiative </p>","PeriodicalId":10811,"journal":{"name":"Critical Care","volume":"34 1","pages":""},"PeriodicalIF":8.8000,"publicationDate":"2025-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Critical Care","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13054-025-05367-x","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CRITICAL CARE MEDICINE","Score":null,"Total":0}
引用次数: 0

Abstract

Dear Editor,

We sincerely appreciate the insightful comments provided by Li et al. [1] regarding our correspondence, “Baricitinib versus tocilizumab in mechanically ventilated patients with COVID-19: a nationwide cohort study” [2], recently published in Critical Care. We recognize the need for further clarification on certain aspects to ensure a more precise interpretation of our study findings.

We acknowledge that the emergence of multiple SARS-CoV-2 variants over time could have influenced the therapeutic efficacy of baricitinib and tocilizumab in critically ill patients with COVID-19. Our cohort analysis accounted for temporal variations by stratifying patients based on their inclusion earlier or later in the pandemic. To provide a more granular assessment, we reanalyzed the outcomes by stratifying them according to the predominant SARS-CoV-2 strains circulating in Korea during the study period: Delta (July 2021–December 2021) and Omicron (January 2022–October 2022). The wild-type and Alpha periods were excluded from the analysis, as baricitinib and tocilizumab had not yet been authorized for use in Korea during these phases. Our findings revealed no significant differences in outcomes between patients receiving baricitinib or tocilizumab during the Delta-dominant period. However, during the Omicron-dominant period, patients treated with baricitinib exhibited significantly lower 30-day mortality rates compared to those receiving tocilizumab (53.8% vs 61.5%; odds ratio 0.73; 95% confidence interval 0.56–0.95). This finding aligns with a previous cohort study demonstrating that baricitinib was more effective in mitigating the inflammatory response triggered by the Omicron variant [3]. Among the 98 of 1630 (6.0%) patients hospitalized due to reinfection, only 14 required mechanical ventilation (MV). Consequently, it was not feasible to determine whether the clinical outcomes associated with baricitinib differed in this subgroup of patients.

As noted by Li et al., the concurrent use of corticosteroids could potentially influence the immunomodulatory effects of baricitinib and tocilizumab. The authors suggested conducting a subgroup analysis based on corticosteroid use. However, nearly all patients (98.4% of the initial cohort) received corticosteroids. Therefore, instead of a binary analysis based on corticosteroid administration, we performed subgroup analyses of 30-day mortality based on corticosteroid dosage and treatment duration. Corticosteroid use was defined as the administration of at least one dose of intravenous dexamethasone, hydrocortisone, or methylprednisolone during hospitalization. To standardize comparisons, all doses were converted to prednisolone equivalents [4]. The cut-off values for daily steroid dose and total treatment duration were determined based on the mean values observed in the study population. Among patients who received corticosteroids for fewer than 12 days or at a daily dose below 60 mg, the baricitinib group exhibited significantly lower mortality rates than the tocilizumab group (Fig. 1). However, when corticosteroid treatment extended to 12 or more days, or when the daily dose reached 60 mg or higher, no significant differences in 30-day mortality were observed between the groups. These findings suggest that the beneficial effects of baricitinib may be more pronounced in patients with critical COVID-19 receiving lower corticosteroid doses. Further studies are warranted to investigate the interplay between corticosteroids, other immunomodulatory agents, and clinical outcomes.

Fig. 1
Abstract Image

Association of baricitinib on 30-day mortality based on corticosteroid dosage and treatment duration. Odds ratios (represented by squares) and 95% CIs (depicted by horizontal lines) were calculated for the baricitinib (n = 553) and tocilizumab (n = 553) groups. CI confidence interval

Full size image

Contrary to the authors’ comment, we had provided the duration of therapy with baricitinib and tocilizumab in the original paper [2]. In both the unmatched and propensity score-matched groups, the median (interquartile range) durations of baricitinib and tocilizumab use were 8 (4–13) days and 1 (1–1) day, respectively. The duration of baricitinib use aligns with previously reported values (7–8 days) [3, 5]. The daily dose of each drug was not calculated, as prescriptions may not always accurately reflect actual treatment. However, based on Korean COVID-19 treatment guidelines [6], the dosage was likely consistent at approximately 4 mg/day for baricitinib and 8 mg/kg/day for tocilizumab. We would like to clarify that baricitinib was associated with lower 30-day mortality than tocilizumab in the overall cohort of patients with COVID-19 requiring MV. This finding contrasts with previous studies that reported no significant benefit of baricitinib in mechanically ventilated patients [7, 8]. As noted by Li et al., the efficacy of baricitinib may be reduced in patients with gastrointestinal malabsorption or renal dysfunction, both of which are frequently observed in those receiving MV [8, 9]. However, the administration of baricitinib over multiple days may ensure more stable drug concentrations. Furthermore, its association with reduced 30-day mortality has been consistently observed in patients undergoing renal replacement therapy.

Among mechanically ventilated patients with COVID-19, baricitinib was associated with lower 30-day mortality than tocilizumab, particularly during the Omicron period and among those receiving lower doses of corticosteroids. We hope these clarifications address the concerns raised by the authors and further enhance the interpretation of our study findings.

All data generated or analyzed during this study are included in this published article.

MV:

Mechanical ventilation

  1. Li R, Wang J, Li Q, Guo Q, Zhao JK, Wei JC, et al. Comments on “Baricitinib versus tocilizumab in mechanically ventilated patients with COVID-19: a nationwide cohort study.” Crit Care. 2024;28:428.

    PubMed PubMed Central Google Scholar

  2. You SH, Baek MS, Kim TW, Jung SY, Kim WY. Baricitinib versus tocilizumab in mechanically ventilated patients with COVID-19: a nationwide cohort study. Crit Care. 2024;28:282.

    PubMed PubMed Central Google Scholar

  3. Sunny S, Tran A, Lee J, Abdallah M, Chaudhry N, Quale J. Comparison of tocilizumab vs baricitinib in clinical outcomes among hospitalized patients with COVID-19: experience from a public hospital system in New York City. Open Forum Infect Dis. 2023;10:ofad26.

    Google Scholar

  4. Meikle AW, Tyler FH. Potency and duration of action of glucocorticoids. Effects of hydrocortisone, prednisone and dexamethasone on human pituitary-adrenal function. Am J Med. 1977;63:200–27.

    CAS PubMed Google Scholar

  5. Peterson JH, Paranjape NS, Grundlingh N, Priestley JL. Outcomes and adverse effects of baricitinib versus tocilizumab in the management of severe COVID-19. Crit Care Med. 2023;51:337–46.

    CAS PubMed Google Scholar

  6. National Medical Center—Office for the Central Infectious Disease Hospital—National Institute of Infectious Diseases. Clinical practice guideline for coronavirus disease 2019 (COVID-19). https://www.nmc.or.kr/icd/bbs/B0000070/list.do?menuNo=1300032 (2022). Accessed 12 Apr 2024.

  7. RECOVERY Collaborative Group. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. Lancet. 2022;400:359–68.

    Google Scholar

  8. Patanwala AE, Xiao X, Hills TE, Higgins AM, McArthur CJ, Alexander GC, et al. Comparative effectiveness of baricitinib versus tocilizumab in hospitalized patients with COVID-19: a retrospective cohort study of the National Covid Collaborative. Crit Care Med. 2025;53:e29-41.

    CAS PubMed Google Scholar

  9. Reintam Blaser A, Poeze M, Malbrain ML, Bjorck M, Oudemans-van Straaten HM, Starkopf J, et al. Gastrointestinal symptoms during the first week of intensive care are associated with poor outcome: a prospective multicentre study. Intens Care Med. 2013;39:899–909.

    Google Scholar

Download references

This study used the database of the Korea Disease Control and Prevention Agency and the National Health Insurance Service for policy and academic research (KDCA-NHIS-2023-1-488).

This research was supported by the National Research Foundation of Korea grant funded by the Korea government (Ministry of Science, ICT & Future Planning) (2022R1F1A1067609). The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication.

Authors and Affiliations

  1. Department of Global Innovative Drugs, The Graduate School of Chung-Ang University, Chung-Ang University, Seoul, Republic of Korea

    Seung-Hun You & Sun-Young Jung

  2. Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Republic of Korea

    Moon Seong Baek, Tae Wan Kim & Won-Young Kim

  3. College of Pharmacy, Chung-Ang University, Seoul, Republic of Korea

    Sun-Young Jung

Authors
  1. Seung-Hun YouView author publications

    You can also search for this author inPubMed Google Scholar

  2. Moon Seong BaekView author publications

    You can also search for this author inPubMed Google Scholar

  3. Tae Wan KimView author publications

    You can also search for this author inPubMed Google Scholar

  4. Sun-Young JungView author publications

    You can also search for this author inPubMed Google Scholar

  5. Won-Young KimView author publications

    You can also search for this author inPubMed Google Scholar

Contributions

WYK participated in the conception and design of study. SYJ and SHY participated in the data acquisition and data analysis. WYK, SYJ, MSB, and TWK participated in the data interpretation. WYK and SHY participated in the draft of the manuscript. SYJ, MSB, and TWK helped to revise the manuscript for important intellectual content. All authors read and approved the final manuscript.

Corresponding authors

Correspondence to Sun-Young Jung or Won-Young Kim.

Ethics approval and consent to participate

The study protocol for the utilization of de-identified patient data was exempt from review by the Institutional Review Board of Chung-Ang University (1041078-20230306-HR-055).

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

Abstract Image

Cite this article

You, SH., Baek, M.S., Kim, T.W. et al. Influence of SARS-CoV-2 variants and corticosteroid use on the effectiveness of baricitinib therapy in critical COVID-19. Crit Care 29, 131 (2025). https://doi.org/10.1186/s13054-025-05367-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s13054-025-05367-x

Share this article

Anyone you share the following link with will be able to read this content:

Sorry, a shareable link is not currently available for this article.

Provided by the Springer Nature SharedIt content-sharing initiative

SARS-CoV-2变体和皮质类固醇的使用对危重COVID-19患者巴利替尼治疗效果的影响
尊敬的编辑,我们衷心感谢Li等人[1]对我们的通信“Baricitinib与tocilizumab在COVID-19机械通气患者中的应用:一项全国性队列研究”[2]发表在最近的Critical Care杂志上。我们认识到需要进一步澄清某些方面,以确保更准确地解释我们的研究结果。我们承认,随着时间的推移,多种SARS-CoV-2变体的出现可能会影响巴西替尼和托珠单抗对COVID-19危重患者的治疗效果。我们的队列分析通过根据患者在大流行早期或后期的纳入对患者进行分层来解释时间变化。为了提供更细致的评估,我们根据研究期间在韩国流行的主要SARS-CoV-2菌株:Delta(2021年7月- 2021年12月)和Omicron(2022年1月- 2022年10月)对结果进行了重新分析。野生型和α期被排除在分析之外,因为baricitinib和tocilizumab在这些阶段尚未被批准在韩国使用。我们的研究结果显示,在delta优势期接受巴西替尼或托珠单抗治疗的患者之间的结果没有显著差异。然而,在欧米克隆优势期,与接受托珠单抗的患者相比,接受巴西替尼治疗的患者30天死亡率显著降低(53.8% vs 61.5%;优势比0.73;95%置信区间0.56-0.95)。这一发现与之前的一项队列研究一致,该研究表明巴西替尼在减轻由Omicron变体[3]引发的炎症反应方面更有效。1630例再感染患者中98例(6.0%),仅14例需要机械通气(MV)。因此,确定与巴西替尼相关的临床结果在该亚组患者中是否不同是不可行的。正如Li等人所指出的,同时使用皮质类固醇可能会影响巴西替尼和托珠单抗的免疫调节作用。作者建议进行基于皮质类固醇使用的亚组分析。然而,几乎所有患者(98.4%的初始队列)都接受了皮质类固醇治疗。因此,我们不是基于皮质类固醇给药的二元分析,而是基于皮质类固醇剂量和治疗时间对30天死亡率进行亚组分析。皮质类固醇的使用定义为住院期间静脉注射至少一剂地塞米松、氢化可的松或甲基强的松。为了使比较标准化,所有剂量均转换为强的松龙当量[4]。每日类固醇剂量和总治疗时间的临界值是根据在研究人群中观察到的平均值确定的。在接受皮质类固醇治疗少于12天或每日剂量低于60mg的患者中,baricitinib组的死亡率明显低于tocilizumab组(图1)。然而,当皮质类固醇治疗延长至12天或更长时间,或每日剂量达到60mg或更高时,两组间30天死亡率无显著差异。这些发现表明,巴西替尼的有益作用可能在接受较低皮质类固醇剂量的危重COVID-19患者中更为明显。需要进一步研究皮质类固醇、其他免疫调节剂和临床结果之间的相互作用。基于皮质类固醇剂量和治疗时间的巴西替尼与30天死亡率的关联。计算baricitinib (n = 553)和tocilizumab (n = 553)组的优势比(以平方表示)和95% ci(以水平线表示)。与作者的评论相反,我们在原始论文[2]中提供了baricitinib和tocilizumab治疗的持续时间。在未匹配组和倾向评分匹配组中,baricitinib和tocilizumab使用的中位(四分位数范围)持续时间分别为8(4-13)天和1(1 - 1)天。巴西替尼的使用时间与先前报道的值一致(7-8天)[3,5]。每种药物的日剂量没有计算,因为处方可能并不总是准确反映实际治疗。然而,根据韩国COVID-19治疗指南[6],巴厘替尼的剂量可能是一致的,约为4mg /天,托珠单抗为8mg /kg/天。我们想要澄清的是,在需要MV的COVID-19患者的总体队列中,巴西替尼与托珠单抗相比具有更低的30天死亡率。这一发现与先前报道baricitinib对机械通气患者无显著益处的研究形成对比[7,8]。正如Li等人所指出的。 胃肠道吸收不良或肾功能不全的患者可能会降低巴西替尼的疗效,这两种情况在接受MV的患者中都很常见[8,9]。然而,连续多天服用巴西替尼可以确保更稳定的药物浓度。此外,在接受肾脏替代治疗的患者中,它与降低30天死亡率的关系一直被观察到。在机械通气的COVID-19患者中,巴西替尼的30天死亡率低于托珠单抗,特别是在欧米克隆期间和接受低剂量皮质类固醇的患者中。我们希望这些澄清能解决作者提出的问题,并进一步加强对我们研究结果的解释。本研究中产生或分析的所有数据都包含在这篇发表的文章中。李锐,王军,李强,郭强,赵建军,魏建军,等。对“Baricitinib与tocilizumab在机械通气的COVID-19患者中的应用:一项全国性队列研究”的评论。危重症护理。2024;28:428。PubMed PubMed Central bbb学者游生,Baek MS, Kim TW, Jung syy, Kim ywin。Baricitinib与tocilizumab在机械通气的COVID-19患者中的应用:一项全国性队列研究危重症护理。2024;28:282。[10]学者Sunny S, Tran A, Lee J, Abdallah M, Chaudhry N, Quale J. tocilizumab与baricitinib在COVID-19住院患者临床结局的比较:来自纽约市公立医院系统的经验。《中华医学会传染病杂志》2009年第10期。[0]学者米克尔AW,泰勒FH。糖皮质激素的效力和作用时间。氢化可的松、强的松和地塞米松对人垂体肾上腺功能的影响。[J] .中华医学杂志。1977;63:200-27。中科院PubMed谷歌学者Peterson JH, Paranjape NS, grundling N, Priestley JL。巴西替尼与托珠单抗在重症COVID-19治疗中的结局和不良反应中华危重症医学杂志[j]; 2009; 31(1): 357 - 357。中国科学院PubMed谷歌学者国家医学中心-中央传染病医院办公室-国家传染病研究所。2019冠状病毒病临床实践指南。https://www.nmc.or.kr/icd/bbs/B0000070/list.do?menuNo=1300032(2022)。2024年4月12日访问。恢复协作小组。Baricitinib治疗COVID-19住院患者(康复):一项随机、对照、开放标签、平台试验和更新的荟萃分析《柳叶刀》杂志。2022;400:359 - 68。[10]学者Patanwala AE, Xiao X, Hills TE, Higgins AM, McArthur CJ, Alexander GC,等。baricitinib与tocilizumab在Covid -19住院患者中的比较有效性:国家Covid协作的回顾性队列研究危重症护理杂志,2015;53:29-41。中科院PubMed bbb学者Reintam Blaser A, Poeze M, Malbrain ML, Bjorck M, Oudemans-van Straaten HM, Starkopf J,等。重症监护第一周的胃肠道症状与预后不良相关:一项前瞻性多中心研究护理医学杂志,2013;39:899-909。本研究使用韩国疾病预防管理院和国民健康保险公团的数据库(KDCA-NHIS-2023-1-488)进行政策和学术研究。本研究由韩国国家研究基金会资助,由韩国政府(Ministry of Science, ICT &amp;未来规划)(2022R1F1A1067609)。资助者在研究的设计和实施中没有任何作用;收集、管理、分析和解释数据;审稿:手稿的准备、审查或批准;或决定投稿发表。韩国首尔中央大学研究生院全球创新药物研究室,中央大学,首尔,韩国;郑善英韩国首尔中央大学医学院中央大学附属医院内科肺重症医学科白文成,金泰完汉城中央大学药学院金元荣韩国asun - young JungAuthorsSeung-Hun YouView作者出版物您也可以在pubmed谷歌ScholarMoon Seong BaekView作者出版物中搜索该作者您也可以在pubmed谷歌ScholarTae Wan KimView作者出版物中搜索该作者您也可以在pubmed谷歌ScholarSun-Young JungView作者出版物中搜索该作者您也可以在pubmed谷歌ScholarWon-Young KimView作者出版物中搜索该作者您也可以在pubmed谷歌ScholarWon-Young KimView作者出版物中搜索该作者swyk参与了研究的构思和设计。SYJ和SHY参与了数据采集和数据分析。WYK、SYJ、MSB、TWK参与数据解释。WYK和SHY参与了稿件的起草。 SYJ, MSB和TWK帮助修改了手稿中重要的知识内容。所有作者都阅读并批准了最终的手稿。通讯作者:郑善英、金元英。伦理批准和参与同意:中央大学机构审查委员会(1041078-20230306-HR-055)豁免了使用未识别患者数据的研究方案。发表同意不适用。利益竞争作者声明没有利益竞争。出版商声明:对于已出版的地图和机构关系中的管辖权要求,普林格·自然保持中立。开放获取本文遵循知识共享署名4.0国际许可协议,该协议允许以任何媒介或格式使用、共享、改编、分发和复制,只要您适当地注明原作者和来源,提供知识共享许可协议的链接,并注明是否进行了更改。本文中的图像或其他第三方材料包含在文章的知识共享许可协议中,除非在材料的署名中另有说明。如果材料未包含在文章的知识共享许可中,并且您的预期用途不被法律法规允许或超过允许的用途,您将需要直接获得版权所有者的许可。要查看本许可协议的副本,请访问http://creativecommons.org/licenses/by/4.0/.Reprints和permissionsCite这篇文章you, SH., Baek, m.s., Kim, T.W.等人。SARS-CoV-2变异和皮质类固醇使用对重症COVID-19患者巴比替尼治疗效果的影响危重症护理29,131(2025)。https://doi.org/10.1186/s13054-025-05367-xDownload citation:收稿日期:2025年3月7日接受日期:2025年3月11日发布日期:2025年3月22日doi: https://doi.org/10.1186/s13054-025-05367-xShare本文任何与您共享以下链接的人都可以阅读此内容:获取可共享链接对不起,本文目前没有可共享链接。复制到剪贴板由施普林格自然共享内容倡议提供
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Critical Care
Critical Care 医学-危重病医学
CiteScore
20.60
自引率
3.30%
发文量
348
审稿时长
1.5 months
期刊介绍: Critical Care is an esteemed international medical journal that undergoes a rigorous peer-review process to maintain its high quality standards. Its primary objective is to enhance the healthcare services offered to critically ill patients. To achieve this, the journal focuses on gathering, exchanging, disseminating, and endorsing evidence-based information that is highly relevant to intensivists. By doing so, Critical Care seeks to provide a thorough and inclusive examination of the intensive care field.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信